Alyeska Investment Group
MAZE

Alyeska Investment Group’s Maze Therapeutics MAZE Stock Holding History

Alyeska Investment Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.98M Sell
100,000
-96,124
-49% -$4.24M 0.01% 527
2025
Q4 		$8.13M Buy
196,124
+71,124
+57% +$2.44M 0.02% 415
2025
Q3 		$3.24M Hold
125,000
– – 0.01% 486
2025
Q2 		$1.53M Hold
125,000
– – 0.01% 487
2025
Q1 		$1.38M Buy
+125,000
New +$1.5M 0.01% 429

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group's MAZE Position: Q1 2026 in Review

Alyeska Investment Group reduced its Maze Therapeutics (MAZE) stake by 49% in Q1 2026, selling an estimated $4.24M and leaving 100,000 shares worth $2.98M. The position accounts for 0.01% of the portfolio, ranked #527.

Alyeska Investment Group first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $8.13M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Alyeska Investment Group held 100,000 shares of Maze Therapeutics worth $2.98M as of Q1 2026.
  • Alyeska Investment Group sold 96,124 Maze Therapeutics shares in Q1 2026, an estimated $4.24M.
  • Maze Therapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #527 holding.
  • Alyeska Investment Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Alyeska Investment Group's Maze Therapeutics position peaked at $8.13M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.